Pharmacological inhibition of RAS overcomes FLT3 inhibitor resistance in FLT3-ITD+ AML through AP-1 and RUNX1

Pharmacological inhibition of RAS overcomes FLT3 inhibitor resistance in FLT3-ITD+ AML through AP-1 and RUNX1

Summary: AML is characterized by mutations in genes associated with growth regulation such as internal tandem duplications (ITD) in the receptor kinase FLT3. Inhibitors targeting FLT3 (FLT3i) are being used to treat patients with FLT3-ITD+ but most relapse and become resistant. To elucidate the resi...

Full description

Bibliographic Details
Main Authors: Daniel J.L. Coleman, Peter Keane, Paulynn S. Chin, Luke Ames, Sophie Kellaway, Helen Blair, Naeem Khan, James Griffin, Elizabeth Holmes, Alexander Maytum, Sandeep Potluri, Lara Strate, Kinga Koscielniak, Manoj Raghavan, John Bushweller, Olaf Heidenreich, Terry Rabbitts, Peter N. Cockerill, Constanze Bonifer
Format: Article
Language:English
Published: Elsevier 2024-04-01
Series:iScience
Subjects:
Pharmacy
Molecular biology
Online Access:http://www.sciencedirect.com/science/article/pii/S2589004224007983

Similar Items

Similar Items